People battling advanced esophageal cancers should get doses of chemotherapy both before and after tumor-removing surgeries, a new study suggests.
Jun 4, 2024
0
0
Scaling back treatment for three kinds of cancer can make life easier for patients without compromising outcomes, doctors reported at the world's largest cancer conference.
Jun 2, 2024
1
99
The American Gastroenterological Association's (AGA) new evidence-based Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia, published today in Gastroenterology, establishes ...
May 17, 2024
0
36
Esophageal squamous cell carcinoma (ESCC) accounts for around 90% of esophageal cancers, especially in East Asia. New findings indicate that periostin, or POSTN, promotes ESCC progression by enhancing cancer and stromal cell ...
Apr 9, 2024
0
1
Eosinophilic esophagitis (EoE) is an allergic inflammatory disorder that affects the esophagus, causing distressing symptoms such as difficulty swallowing in adolescents and adults, and vomiting and abdominal pain in children.
Feb 27, 2024
0
0
The U.S. Food and Drug Administration has approved Takeda's Eohilia (budesonide oral suspension) as the first and only oral treatment for eosinophilic esophagitis (EoE).
Feb 19, 2024
0
1
Children and young adults with allergies or eczema who have difficulty swallowing may have eosinophilic esophagitis. A review published in CMAJ (Canadian Medical Association Journal) provides guidance on how to diagnose and ...
Feb 5, 2024
0
12
A multidisciplinary team of researchers that included 14 graduate students from The University of Texas at Arlington has created a new framework to provide optimal personalized treatment options for individuals with esophageal ...
Jan 31, 2024
0
0
Drinking alcohol—even in moderation—can take a serious toll on the body. According to the National Cancer Institute, there is a strong scientific consensus that drinking alcohol increases the risk for several types of ...
Jan 30, 2024
0
1
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) for the treatment of pediatric patients (aged one to 11 years) with eosinophilic esophagitis (EoE).
Jan 30, 2024
0
7
